Stromal CD10 Expression in Invasive Breast Carcinoma in Correlation with ER, PR and Her2 Status and Tumor Grade.

Abstract

Background: Increasing prevalence of breast cancer in our population is a leading cause of morbidity and mortality. Association of the tumor markers with the behavior of tumor cells may pave a way to better outcomes. Objectives: To investigate the frequency of Stromal CD10 expression in invasive breast carcinoma in correlation with ER, PR and Her2 status and tumor grade.Material and Methods: A total of 102 diagnosed cases of breast carcinoma who underwent mastectomies were examined. Immunohistochemistry was performed for Cluster of differentiation 10 (CD10), Estrogen receptor(ER) Progesterone receptor (PR) and Human epidermal receptor factor 2(HER2)for all the samples. Demographic characteristics and immunopathological variables were recorded. Results: Mean age of the participants was 54.05 ± 8.58 years. Immunohistochemical analysis revealed 83 (81.3%) cases as CD10 positive out of which 15 (14.7%) specimens were weak positive and 68 (66.6%) were strong positive. The expression of CD10 was significantly greater for patients with higher tumor grades (p-value 0.014). Significant association of stromal CD10 expression and ER negativity was observed (p-value < 0.01). Out of 83 (81.3%) specimens that revealed positive CD10 expression, 64 (62.7%) were found HER2 positive and 19(18.6%) were HER2 negative signifying a positive correlation with p-value of <0.01. Conclusion: Frequency of stromal CD10 expression is significantly associated with increasing tumor grade, HER2 positivity and ER negativity. It employs a prognostic role in predicting the aggressiveness of tumor as indicated by higher tumor grade and preemptive therapy with anti CD10 antibody may be beneficial in such candidates.Keywords: Breast carcinoma, CD10, ER, PR, HER2.